<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35231173</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6025</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>85</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of natural products</Title>
          <ISOAbbreviation>J Nat Prod</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High-Content Screening Pipeline for Natural Products Targeting Oncogenic Signaling in Melanoma.</ArticleTitle>
        <Pagination>
          <StartPage>1006</StartPage>
          <EndPage>1017</EndPage>
          <MedlinePgn>1006-1017</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jnatprod.1c01154</ELocationID>
        <Abstract>
          <AbstractText>The incidence of melanoma, the most fatal dermatological cancer, has dramatically increased over the last few decades. Modern targeted therapy with kinase inhibitors induces potent clinical responses, but drug resistance quickly develops. Combination therapy improves treatment outcomes. Therefore, novel inhibitors targeting aberrant proliferative signaling in melanoma via the MAPK/ERK and PI3K/AKT pathways are urgently needed. Biosensors were combined that report on ERK/AKT activity with image-based high-content screening and HPLC-based activity profiling. An in-house library of 2576 plant extracts was screened on two melanoma cell lines with different oncogenic mutations leading to pathological ERK/AKT activity. Out of 140 plant extract hits, 44 were selected for HPLC activity profiling. Active thymol derivatives and piperamides from <i>Arnica montana</i> and <i>Piper nigrum</i> were identified that inhibited pathological ERK and/or AKT activity. The pipeline used enabled an efficient identification of natural products targeting oncogenic signaling in melanoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dürr</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hell</LastName>
            <ForeName>Tanja</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-8867-2412</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dobrzyński</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mattei</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>John</LastName>
            <ForeName>Anika</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Augsburger</LastName>
            <ForeName>Nathanja</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bradanini</LastName>
            <ForeName>Gloria</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reinhardt</LastName>
            <ForeName>Jakob K</ForeName>
            <Initials>JK</Initials>
            <Identifier Source="ORCID">0000-0002-8675-1029</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossberg</LastName>
            <ForeName>Florian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drobnjakovic</LastName>
            <ForeName>Milos</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Mahabir P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacognostic Research and Panamanian Flora, Faculty of Pharmacy, University of Panama, Panama City 0801, Republic of Panama.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamburger</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9331-273X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pertz</LastName>
            <ForeName>Olivier</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0001-8579-4919</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garo</LastName>
            <ForeName>Eliane</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-3497-2524</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nat Prod</MedlineTA>
        <NlmUniqueID>7906882</NlmUniqueID>
        <ISSNLinking>0163-3864</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35231173</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jnatprod.1c01154</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
